Cagrilintide and semaglutide 2.4 mg is a once-weekly combo studied for weight loss. Learn how it works, trial results, dosing, side effects, and safety.
Cagrilintide and semaglutide 2.4 mg is an investigational once-weekly injection that pairs an amylin analog with the GLP-1 drug used in Wegovy. In the phase 3 REDEFINE 1 trial, the combination produced average weight loss of roughly 20% to 23% over 68 weeks in adults with obesity or overweight. CagriSema is not FDA-approved for weight loss or any other use in the United States.
What Is Cagrilintide and Semaglutide 2.4 mg?
CagriSema is a fixed-dose combination product. Each weekly dose contains 2.4 mg of cagrilintide and 2.4 mg of semaglutide in one pre-filled pen.
- Cagrilintide is a long-acting amylin analog. It mimics amylin, a hormone the pancreas releases alongside insulin after meals.
- Semaglutide 2.4 mg is the highest approved dose of the GLP-1 receptor agonist sold as Wegovy for chronic weight management.
Researchers studying cagrilintide and semaglutide describe the pairing as targeting two separate appetite pathways instead of one.
How the Two Drugs Work Together
Amylin and GLP-1 are both released after eating, and both tell the brain to reduce food intake. They act on different receptors and different brain regions, which is why scientists tested them as a pair.
Semaglutide slows gastric emptying and increases fullness signals. Cagrilintide works mainly in the hindbrain to blunt appetite and delay stomach emptying. Because the two mechanisms only partly overlap, the effects may add up.
Neither drug is a fat burner. Both work by reducing how much a person eats and how hungry they feel.
What the REDEFINE Trials Found
REDEFINE 1 enrolled 3,417 adults with obesity or overweight plus at least one related health condition, and none of them had type 2 diabetes. Treatment lasted 68 weeks.
- Average weight loss was 20.4% across all participants who started treatment.
- Among people who reached and stayed on the full 2.4 mg / 2.4 mg dose, average weight loss was 22.7%.
- The trial met its primary endpoint, but the company's earlier 25% goal was not reached.
REDEFINE 2 tested the same combination in adults with type 2 diabetes and reported roughly 13.7% average weight loss at 68 weeks.
Many people search for semaglutide before and after images to set expectations. Trial averages describe groups rather than individuals, and real-world results vary widely from person to person.
Cagrilintide Semaglutide Dosage and Titration
Both drugs are given together once a week as a subcutaneous injection. The cagrilintide semaglutide dosage schedule used in phase 3 trials started low and escalated about every four weeks until participants reached the maintenance dose of 2.4 mg plus 2.4 mg.
Slow escalation is standard for this drug class because it reduces nausea and other gastrointestinal side effects during the first weeks of treatment.
There is no approved dosing schedule to follow, because the product is not on the market. Vials sold by unregulated online vendors are not the same product that was studied in clinical trials.
How It Compares With Other Weight Loss Medications
Cross-trial comparisons are rough guides only. Each study used different populations, treatment durations, and statistical methods, so the numbers below do not prove that one drug is better than another.
| Treatment | Average weight loss in trials | Status |
|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | About 15% at 68 weeks (STEP 1) | FDA-approved |
| Tirzepatide 15 mg (Zepbound) | About 21% at 72 weeks (SURMOUNT-1) | FDA-approved |
| Cagrilintide plus semaglutide 2.4 mg | About 20% to 23% at 68 weeks (REDEFINE 1) | Investigational |
| Retatrutide 12 mg | About 24% at 48 weeks (phase 2) | Investigational |
Some people discuss stacking retatrutide and semaglutide or mixing other injectables without medical supervision. Combining prescription weight loss drugs on your own raises the risk of severe nausea, dehydration, and low blood sugar.
Side Effects and Safety Considerations
Gastrointestinal symptoms are the most common complaints with both drugs. Most are mild to moderate and ease once the body adjusts to a dose.
- Nausea, vomiting, diarrhea, and constipation
- Injection site reactions such as redness or swelling
- Fatigue and headache
- Gallbladder disease and pancreatitis, reported with GLP-1 medications
Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents. It is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2.
Semaglutide and pregnancy should not overlap. The label advises stopping semaglutide at least two months before a planned pregnancy, and weight loss medications are not recommended during breastfeeding.
Anyone using these drugs alongside insulin or a sulfonylurea needs monitoring for low blood sugar. Talk with a healthcare professional about your medical history before starting any GLP-1 or amylin-based therapy.
Regulatory Status and Availability
CagriSema is not approved by the FDA or any other major regulator as of 2025. Novo Nordisk has said it plans to file for regulatory review in early 2026.
Until then, the combination is available only to people enrolled in clinical trials. Compounded products marketed as CagriSema are not FDA-approved and have not been tested for purity, potency, or safety.
If you are seeking treatment today, FDA-approved options such as semaglutide 2.4 mg and tirzepatide are available by prescription and require ongoing medical follow-up.
Frequently Asked Questions
Is cagrilintide and semaglutide 2.4 mg FDA approved?
No. As of 2025, CagriSema has not been approved by the FDA or any other major regulator. Novo Nordisk has stated that it plans to submit the combination for regulatory review in early 2026, so it is currently available only through clinical trials.
How much weight do people lose on cagrilintide and semaglutide 2.4 mg?
In the REDEFINE 1 trial, participants lost an average of 20.4% of their body weight over 68 weeks, and those who stayed on the full 2.4 mg / 2.4 mg dose averaged 22.7%. A separate trial in adults with type 2 diabetes reported about 13.7% average weight loss. Individual results vary widely.
What are the side effects of cagrilintide and semaglutide 2.4 mg?
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, and they usually ease as the dose stabilizes. Less common but serious risks include gallbladder disease, pancreatitis, and low blood sugar when combined with insulin or sulfonylureas. Semaglutide also carries a boxed warning about thyroid C-cell tumors.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.